- Home
- STTK vs LLAP Comparison
STTK vs LLAP Comparison
Compare STTK & LLAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- LLAP
- Stock Information
- Founded
- STTK 2016
- LLAP 2013
- Country
- STTK United States
- LLAP United States
- Employees
- STTK N/A
- LLAP N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- LLAP Military/Government/Technical
- Sector
- STTK Health Care
- LLAP Industrials
- Exchange
- STTK Nasdaq
- LLAP Nasdaq
- Market Cap
- STTK 173.6M
- LLAP 165.7M
- IPO Year
- STTK 2020
- LLAP N/A
- Fundamental
- Price
- STTK $3.84
- LLAP $0.25
- Analyst Decision
- STTK Strong Buy
- LLAP Buy
- Analyst Count
- STTK 3
- LLAP 3
- Target Price
- STTK $10.67
- LLAP $2.58
- AVG Volume (30 Days)
- STTK 123.8K
- LLAP 8.7M
- Earning Date
- STTK 11-07-2024
- LLAP 11-12-2024
- Dividend Yield
- STTK N/A
- LLAP N/A
- EPS Growth
- STTK N/A
- LLAP N/A
- EPS
- STTK N/A
- LLAP N/A
- Revenue
- STTK $4,123,999.00
- LLAP $133,107,000.00
- Revenue This Year
- STTK $164.45
- LLAP $8.71
- Revenue Next Year
- STTK N/A
- LLAP $34.59
- P/E Ratio
- STTK N/A
- LLAP N/A
- Revenue Growth
- STTK 380.09
- LLAP 10.75
- 52 Week Low
- STTK $1.33
- LLAP $0.23
- 52 Week High
- STTK $11.76
- LLAP $1.62
- Technical
- Relative Strength Index (RSI)
- STTK 53.41
- LLAP 28.11
- Support Level
- STTK $3.63
- LLAP $0.24
- Resistance Level
- STTK $3.94
- LLAP $0.27
- Average True Range (ATR)
- STTK 0.22
- LLAP 0.01
- MACD
- STTK 0.06
- LLAP 0.02
- Stochastic Oscillator
- STTK 64.91
- LLAP 25.86
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About LLAP Terran Orbital Corporation
Terran Orbital Corp is a manufacturer of satellite products primarily serving the aerospace and defense industries. The company provide end-to-end satellite solutions by combining satellite design, production, launch planning, mission operations, and on-orbit support to meet the needs of our military, civil, and commercial customers. Geographically company operates in United States and Europe. Majority of the revenue is generated from United States.